Exploiting Natural Diversity of AAV for the Design of Vectors with Novel Properties

Methods in Molecular Biology

Volumn 807, Issue , 2011, Pages 93-118

  Gao, Guangping ^a   Zhong, Li ^a   Danos, Olivier ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AAV; AAV isolation; AAV2; Amplicon; Molecular rescue; Pseudotyped vector

Indexed keywords

ADENO ASSOCIATED VIRUS; AGAR GEL ELECTROPHORESIS; ANIMAL; ARTICLE; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; POLYMERASE CHAIN REACTION;

ANIMALS; DEPENDOVIRUS; ELECTROPHORESIS, AGAR GEL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; POLYMERASE CHAIN REACTION;

EID: 83455195614     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-370-7_4     Document Type: Chapter

References (167)

1. Blacklow, N. R., Hoggan, M. D., and Rowe, W. P. (1967) Isolation of adenovirus-associ-ated viruses from man, Proc Natl Acad Sci USA 58, 1410–1415.
2. Chen, C.-L., Jensen, R. L., Schnepp, B. C., Connell, M. J., Shell, R., Sferra, T. J., Bartlett, J. S., Clark, K. R., and Johnson, P. R. (2005) Molecular Characterization of Adeno-Associated Viruses Infecting Children, J Virol 79, 14781–14792.
3. Schnepp, B. C., Jensen, R. L., Chen, C. L., Johnson, P. R., and Clark, K. R. (2005) Characterization of adeno-associated virus genomes isolated from human tissues, J Virol 79, 14793–14803.
4. Schnepp, B. C., Jensen, R. L., Clark, K. R., and Johnson, P. R. (2009) Infectious molecular clones of adeno-associated virus isolated directly from human tissues, J Virol 83, 1456–1464.
5. Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., and Wilson, J. M. (2003) Adeno-associated viruses undergo substantial evolution in primates during natural infections, Proc Natl Acad Sci USA 100, 6081–6086.
6. Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., and Wilson, J. M. (2004) Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues, J Virol 78, 6381–6388.
7. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., and Wilson, J. M. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci USA 99, 11854–11859.
8. Gao, G., Vandenberghe, L. H., and Wilson, J. M. (2005) New recombinant serotypes of AAV vectors, Curr Gene Ther 5, 285–297.
9. Duffy, S., Shackelton, L. A., and Holmes, E. C. (2008) Rates of evolutionary change in viruses: patterns and determinants, Nat Rev Genet 9, 267–276.
10. Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., and Wilson, J. M. (1999) Gene Therapy Vectors Based on Adeno-Associated Virus Type 1, J Virol 73, 3994–4003.
11. Takeuchi, Y., Myers, R., and Danos, O. (2008) Recombination and population mosaic of a multifunctional viral gene, adeno-associated virus cap, PLoS ONE 3, e1634.
12. Opie, S. R., Warrington, K. H., Jr., Agbandje-McKenna, M., Zolotukhin, S., and Muzyczka, N. (2003) Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding, J Virol 77, 6995–7006.
13. Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., and Agbandje-McKenna, M. (2009) Heparin binding induces conformational changes in Adeno-associated virus serotype 2, J Struct Biol 165, 146–156.
14. Vandenberghe, L. H., Breous, E., Nam, H. J., Gao, G., Xiao, R., Sandhu, A., Johnston, J., Debyser, Z., Agbandje-McKenna, M., and Wilson, J. M. (2009) Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints, Gene Ther 16, 1416–1428.
15. Grieger, J. C., Snowdy, S., and Samulski, R. J. (2006) Separate Basic Region Motifs within the Adeno-Associated Virus Capsid Proteins Are Essential for Infectivity and Assembly, J Virol 80, 5199–5210.
16. Excoffon, K. J., Koerber, J. T., Dickey, D. D., Murtha, M., Keshavjee, S., Kaspar, B. K., Zabner, J., and Schaffer, D. V. (2009) Directed evolution of adeno-associated virus to an infectious respiratory virus, Proc Natl Acad Sci USA 106, 3865–3870.
17. Ward, P., and Walsh, C. E. (2009) Chimeric AAV Cap sequences alter gene transduction, Virology 386, 237–248.
18. Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., and Wilson, J. M. (2009) The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques, Mol Ther 18, 126–134.
19. Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., and Wilson, J. M. (2009) Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses, J Infect Dis 199, 381–390.
20. Pattison, J. (1988) Parvovirus and human disease. CRC Press, Boca Raton.
21. Halbert, C. L., Miller, A. D., McNamara, S., Emerson, J., Gibson, R. L., Ramsey, B., and Aitken, M. L. (2006) Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors, Hum Gene Ther 17, 440–447.
22. Chirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., and Wilson, J. M. (2000) Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle, J Virol 74, 2420–2425.
23. Mori, S., Takeuchi, T., Enomoto, Y., Kondo, K., Sato, K., Ono, F., Sata, T., and Kanda, T. (2008) Tissue distribution of cynomolgus adeno-associated viruses AAV10, AAV11, and AAVcy.7 in naturally infected monkeys, Arch Virol 153, 375–380.
24. Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J. A. (2008) Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycan-independent transduction activity, J Virol 82, 1399–1406.
25. Halbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., and Miller, A. D. (2000) Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes, J Virol 74, 1524–1532.
26. Peden, C. S., Burger, C., Muzyczka, N., and Mandel, R. J. (2004) Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain, J Virol 78, 6344–6359.
27. Riviere, C., Danos, O., and Douar, A. M. (2006) Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice, Gene Ther 13, 1300–1308.
28. Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., Spencer, C., Byrne, B. J., Wilson, J. M., and Flotte, T. R. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy, Proc Natl Acad Sci USA 106, 16363–16368.
29. Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R. J. (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J Virol 76, 791–801.
30. Wu, Z., Asokan, A., and Samulski, R. J. (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy, Mol Ther 14, 316–327.
31. Van Vliet, K. M., Blouin, V., Brument, N., Agbandje-McKenna, M., and Snyder, R. O. (2008) The role of the adeno-associated virus capsid in gene transfer, Methods Mol Biol 437, 51–91.
32. Wright, J. F. (2009) Transient Transfection Methods for Clinical Adeno-Associated Viral Vector Production, Hum Gene Ther 20, 698–706.
33. Kang, W., Wang, L., Harrell, H., Liu, J., Thomas, D. L., Mayfield, T. L., Scotti, M. M., Ye, G. J., Veres, G., and Knop, D. R. (2009) An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes, Gene Ther 16, 229–239.
34. Smith, R. H., Levy, J. R., and Kotin, R. M. (2009) A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells, Mol Ther 17, 1888–1896.
35. Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., and Samulski, R. J. (2004) Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups, J Virol 78, 4421–4432.
36. Kohlbrenner, E., Aslanidi, G., Nash, K., Shklyaev, S., Campbell-Thompson, M., Byrne, B. J., Snyder, R. O., Muzyczka, N., Warrington, K. H., Jr., and Zolotukhin, S. (2005) Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system, Mol Ther 12, 1217–1225.
37. Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., Cutillo, L., Sparrow, J. R., Williams, D. S., Bennett, J., and Auricchio, A. (2008) Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice, J Clin Invest 118, 1955–1964.
38. Lai, Y., Yue, Y., and Duan, D. (2010) Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome >/= 8.2 kb, Mol Ther 18, 75–79.
39. Dong, B., Nakai, H., and Xiao, W. (2009) Characterization of Genome Integrity for Oversized Recombinant AAV Vector, Mol Ther 18, 87–92.
40. Gao, G. P., Lu, Y., Sun, X., Johnston, J., Calcedo, R., Grant, R., and Wilson, J. M. (2006) High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes, J Virol 80, 6192–6194.
41. Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Jr., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., and Srivastava, A. (2008) Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses, Proc Natl Acad Sci USA 105, 7827–7832.
42. Hewitt, F. C., Li, C., Gray, S. J., Cockrell, S., Washburn, M., and Samulski, R. J. (2009) Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors, J Virol 83, 3919–3929.
43. Paneda, A., Vanrell, L., Mauleon, I., Crettaz, J. S., Berraondo, P., Timmermans, E. J., Beattie, S. G., Twisk, J., van Deventer, S., Prieto, J., Fontanellas, A., Rodriguez-Pena, M. S., and Gonzalez-Aseguinolaza, G. (2009) Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders, Hum Gene Ther 20, 908–917.
44. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J. E. (2008) Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection, Mol Ther 16, 1073–1080.
45. Hauck, B., and Xiao, W. (2003) Characterization of tissue tropism determinants of adeno-associated virus type 1, J Virol 77, 2768–2774.
46. Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., and Chiorini, J. A. (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system, Proc Natl Acad Sci USA 97, 3428–3432.
47. Lin, D., Fantz, C. R., Levy, B., Rafi, M. A., Vogler, C., Wenger, D. A., and Sands, M. S. (2005) AAV2/5 vector expressing galactocer-ebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2, Mol Ther 12, 422–430.
48. Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., and Xiao, X. (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart, Nat Biotechnol 23, 321–328.
49. Mitchell, M., Nam, H. J., Carter, A., McCall, A., Rence, C., Bennett, A., Gurda, B., McKenna, R., Porter, M., Sakai, Y., Byrne, B. J., Muzyczka, N., Aslanidi, G., Zolotukhin, S., and Agbandje-McKenna, M. (2009) Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 9, Acta Crystallogr Sect F Struct Biol Cryst Commun 65, 715–718.
50. Nathwani, A. C., Cochrane, M., McIntosh, J., Ng, C. Y., Zhou, J., Gray, J. T., and Davidoff, A. M. (2009) Enhancing transduction of the liver by adeno-associated viral vectors, Gene Ther 16, 60–69.
51. Ponnazhagan, S., Mukherjee, P., Yoder, M. C., Wang, X. S., Zhou, S. Z., Kaplan, J., Wadsworth, S., and Srivastava, A. (1997) Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice, Gene 190, 203–210.
52. Koeberl, D. D., Alexander, I. E., Halbert, C. L., Russell, D. W., and Miller, A. D. (1997) Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors, Proc Natl Acad Sci USA 94, 1426–1431.
53. Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., Thompson, A. R., and Kay, M. A. (1997) Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors, Nat Genet 16, 270–276.
54. Harding, T. C., Koprivnikar, K. E., Tu, G. H., Zayek, N., Lew, S., Subramanian, A., Sivakumaran, A., Frey, D., Ho, K., VanRoey, M. J., Nichols, T. C., Bellinger, D. A., Yendluri, S., Waugh, J., McArthur, J., Veres, G., and Donahue, B. A. (2004) Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B, Gene Ther 11, 204–213.
55. Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., McTiernan, C. F., Kay, M. A., and Nakai, H. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8, Mol Ther 14, 45–53.
56. Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., and Chamberlain, J. S. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors, Nat Med 10, 828–834.
57. Nathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G., and Davidoff, A. M. (2007) Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates, Blood 109, 1414–1421.
58. Nakai, H., Wu, X., Fuess, S., Storm, T. A., Munroe, D., Montini, E., Burgess, S. M., Grompe, M., and Kay, M. A. (2005) Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver, J Virol 79, 3606–3614.
59. Sarkar, R., Tetreault, R., Gao, G., Wang, L., Bell, P., Chandler, R., Wilson, J. M., and Kazazian, H. H., Jr. (2004) Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype, Blood 103, 1253–1260.
60. Davidoff, A. M., Ng, C. Y., Zhou, J., Spence, Y., and Nathwani, A. C. (2003) Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway, Blood 102, 480–488.
61. Yue, Y., Ghosh, A., Long, C., Bostick, B., Smith, B. F., Kornegay, J. N., and Duan, D. (2008) A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs, Mol Ther 16, 1944–1952.
62. Pacak, C. A., Sakai, Y., Thattaliyath, B. D., Mah, C. S., and Byrne, B. J. (2008) Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice, Genet Vaccines Ther 6, 13.
63. Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., and Byrne, B. J. (2006) Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo, Circ Res 99, e3-9.
64. Fechner, H., Sipo, I., Westermann, D., Pinkert, S., Wang, X., Suckau, L., Kurreck, J., Zeichhardt, H., Muller, O., Vetter, R., Erdmann, V., Tschope, C., and Poller, W. (2008) Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopa-thy, J Mol Med 86, 987–997.
65. Bostick, B., Yue, Y., Lai, Y., Long, C., Li, D., and Dongsheng, D. (2008) AAV-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice, Hum Gene Ther 19, 851-856.
66. Goehringer, C., Rutschow, D., Bauer, R., Schinkel, S., Weichenhan, D., Bekeredjian, R., Straub, V., Kleinschmidt, J. A., Katus, H. A., and Muller, O. J. (2009) Prevention of car-diomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors, Cardiovasc Res 82, 404–410.
67. Ogura, T., Mizukami, H., Mimuro, J., Madoiwa, S., Okada, T., Matsushita, T., Urabe, M., Kume, A., Hamada, H., Yoshikawa, H., Sakata, Y., and Ozawa, K. (2006) Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer, J Gene Med 8, 990–997.
68. Foust, K. D., Poirier, A., Pacak, C. A., Mandel, R. J., and Flotte, T. R. (2008) Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons, Hum Gene Ther 19, 61–70.
69. Wang, Z., Zhu, T., Rehman, K. K., Bertera, S., Zhang, J., Chen, C., Papworth, G., Watkins, S., Trucco, M., Robbins, P. D., Li, J., and Xiao, X. (2006) Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes, Diabetes 55, 875–884.
70. Halbert, C. L., Standaert, T. A., Aitken, M. L., Alexander, I. E., Russell, D. W., and Miller, A. D. (1997) Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration, J Virol 71, 5932–5941.
71. Liqun Wang, R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T. R. (2009) Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antit-rypsin using invasive and noninvasive delivery, Mol Ther 17, 81–87.
72. Mease, P. J., Hobbs, K., Chalmers, A., El-Gabalawy, H., Bookman, A., Keystone, E., Furst, D. E., Anklesaria, P., and Heald, A. E. (2009) Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study, Ann Rheum Dis 68, 1247–1254.
73. Ghosh, A., Allamarvdasht, M., Pan, C. J., Sun, M. S., Mansfield, B. C., Byrne, B. J., and Chou, J. Y. (2006) Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-medi-ated gene transfer, Gene Ther 13, 321–329.
74. Bostick, B., Ghosh, A., Yue, Y., Long, C., and Duan, D. (2007) Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration, Gene Ther 14, 1605–1609.
75. Daly, T. M., Okuyama, T., Vogler, C., Haskins, M. E., Muzyczka, N., and Sands, M. S. (1999) Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice, Hum Gene Ther 10, 85–94.
76. Niemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., and Lothrop, C. D., Jr. (2009) Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood 113, 797–806.
77. Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., Podsakoff, G. M., Nichols, T. C., Kurtzman, G. J., and High, K. A. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector, Nat Med 5, 56–63.
78. Arruda, V. R., Schuettrumpf, J., Herzog, R. W., Nichols, T. C., Robinson, N., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L. B., and High, K. A. (2004) Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1, Blood 103, 85–92.
79. Jiang, H., Lillicrap, D., Patarroyo-White, S., Liu, T., Qian, X., Scallan, C. D., Powell, S., Keller, T., McMurray, M., Labelle, A., Nagy, D., Vargas, J. A., Zhou, S., Couto, L. B., and Pierce, G. F. (2006) Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs, Blood 108, 107–115.
80. Sarkar, R., Mucci, M., Addya, S., Tetreault, R., Bellinger, D. A., Nichols, T. C., and Kazazian, H. H., Jr. (2006) Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice, Hum Gene Ther 17, 427–439.
81. Gao, G., Lu, Y., Calcedo, R., Grant, R. L., Bell, P., Wang, L., Figueredo, J., Lock, M., and Wilson, J. M. (2006) Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates, Mol Ther 13, 77–87.
82. Qiao, C., Li, J., Zheng, H., Bogan, J., Yuan, Z., Zhang, C., Bogan, D., Kornegay, J., and Xiao, X. (2009) Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth, Hum Gene Ther 20, 1–10.
83. Ohshima, S., Shin, J. H., Yuasa, K., Nishiyama, A., Kira, J., Okada, T., and Takeda, S. (2009) Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle, Mol Ther 17, 73–80.
84. Rodino-Klapac, L. R., Montgomery, C. L., Bremer, W. G., Shontz, K. M., Malik, V., Davis, N., Sprinkle, S., Campbell, K. J., Sahenk, Z., Clark, K. R., Walker, C. M., Mendell, J. R., and Chicoine, L. G. (2010) Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery, Mol Ther 18, 109–117.
85. Bish, L. T., Sleeper, M. M., Brainard, B., Cole, S., Russell, N., Withnall, E., Arndt, J., Reynolds, C., Davison, E., Sanmiguel, J., Wu, D., Gao, G., Wilson, J. M., and Sweeney, H. L. (2008) Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines, Mol Ther 16, 1953–1959.
86. During, M. J., Samulski, R. J., Elsworth, J. D., Kaplitt, M. G., Leone, P., Xiao, X., Li, J., Freese, A., Taylor, J. R., Roth, R. H., Sladek, J. R., Jr., O’Malley, K. L., and Redmond, D. E., Jr. (1998) In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector, Gene Ther 5, 820–827.
87. Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B., and Cunningham, J. (2006) Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC, Mol Ther 20, 350–360.
88. Ciron, C., Cressant, A., Roux, F., Raoul, S., Cherel, Y., Hantraye, P., Deglon, N., Schwartz, B., Barkats, M., Heard, J. M., Tardieu, M., Moullier, P., and Colle, M. A. (2009) Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution, Hum Gene Ther 20, 350–360.
89. Eslamboli, A., Romero-Ramos, M., Burger, C., Bjorklund, T., Muzyczka, N., Mandel, R. J., Baker, H., Ridley, R. M., and Kirik, D. (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain, Brain 130, 799–815.
90. Colle, M. A., Piguet, F., Bertrand, L., Raoul, S., Bieche, I., Dubreil, L., Sloothaak, D., Bouquet, C., Moullier, P., Aubourg, P., Cherel, Y., Cartier, N., and Sevin, C. (2010) Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate, Hum Mol Genet 19, 147–158.
91. Bennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., Gao, G. P., Nyberg, W. C., Tazelaar, J., Hughes, J., Wilson, J. M., and Jacobson, S. G. (1999) Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina, Proc Natl Acad Sci USA 96, 9920–9925.
92. Lotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., and Davidson, B. L. (2003) Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina, Hum Gene Ther 14, 1663–1671.
93. Jacobson, S. G., Boye, S. L., Aleman, T. S., Conlon, T. J., Zeiss, C. J., Roman, A. J., Cideciyan, A. V., Schwartz, S. B., Komaromy, A. M., Doobrajh, M., Cheung, A. Y., Sumaroka, A., Pearce-Kelling, S. E., Aguirre, G. D., Kaushal, S., Maguire, A. M., Flotte, T. R., and Hauswirth, W. W. (2006) Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis, Hum Gene Ther 17, 845–858.
94. Stieger, K., Schroeder, J., Provost, N., Mendes-Madeira, A., Belbellaa, B., Le Meur, G., Weber, M., Deschamps, J. Y., Lorenz, B., Moullier, P., and Rolling, F. (2009) Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates, Mol Ther 17, 516–523.
95. Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, A., Leonard, D., Wright, J. F., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H. C., High, K. A., and Kay, M. A. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med 12, 342–347.
96. Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C., and High, K. A. (2007) CD8(+) T-cell responses to adeno-associated virus capsid in humans, Nat Med 13, 419–422.
97. Herzog, R. W. (2007) Immune responses to AAV capsid: are mice not humans after all? Mol Ther 15, 649–650.
98. Bainbridge, J. W., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S. S., Thrasher, A. J., Fitzke, F. W., Carter, B. J., Rubin, G. S., Moore, A. T., and Ali, R. R. (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis, N Engl J Med 358, 2231–2239.
99. Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell’Osso, L., Hertle, R., Ma, J. X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., and Bennett, J. (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis, N Engl J Med 358, 2240–2248.
100. Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., and Jacobson, S. G. (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial, Hum Gene Ther 19, 979–990.
101. Gao, G., Vandenberghe, L. H., and Wilson, J. M. (2005) New recombinant serotypes of AAV vectors, Curr Gene Ther 5, 285–297.
102. Vandenberghe, L. H., Wilson, J. M., and Gao, G. (2009) Tailoring the AAV vector capsid for gene therapy, Gene Ther 16, 311–319.
103. Du, L., Kido, M., Lee, D. V., Rabinowitz, J. E., Samulski, R. J., Jamieson, S. W., Weitzman, M. D., and Thistlethwaite, P. A. (2004) Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors, Mol Ther 10, 604–608.
104. Palomeque, J., Chemaly, E. R., Colosi, P., Wellman, J. A., Zhou, S., Del Monte, F., and Hajjar, R. J. (2007) Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo, Gene Ther 14, 989–997.
105. Yan, Z., Lei-Butters, D. C., Liu, X., Zhang, Y., Zhang, L., Luo, M., Zak, R., and Engelhardt, J. F. (2006) Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia, J Biol Chem 281, 29684–29692.
106. Lorain, S., Gross, D. A., Goyenvalle, A., Danos, O., Davoust, J., and Garcia, L. (2008) Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles, Mol Ther 16, 541–547.
107. Vite, C. H., Passini, M. A., Haskins, M. E., and Wolfe, J. H. (2003) Adeno-associated virus vector-mediated transduction in the cat brain, Gene Ther 10, 1874–1881.
108. Kawase, Y., Ly, H. Q., Prunier, F., Lebeche, D., Shi, Y., Jin, H., Hadri, L., Yoneyama, R., Hoshino, K., Takewa, Y., Sakata, S., Peluso, R., Zsebo, K., Gwathmey, J. K., Tardif, J. C., Tanguay, J. F., and Hajjar, R. J. (2008) Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure, J Am Coll Cardiol 51, 1112–1119.
109. Byrne, M. J., Power, J. M., Preovolos, A., Mariani, J. A., Hajjar, R. J., and Kaye, D. M. (2008) Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals, Gene Ther 15, 1550–1557.
110. Liu, X., Luo, M., Guo, C., Yan, Z., Wang, Y., and Engelhardt, J. F. (2007) Comparative biology of rAAV transduction in ferret, pig and human airway epithelia, Gene Ther 14, 1543–1548.
111. Flotte, T. R., Fischer, A. C., Goetzmann, J., Mueller, C., Cebotaru, L., Yan, Z., Wang, L., Wilson, J. M., Guggino, W. B., and Engelhardt, J. F. (2010) Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway, Mol Ther 18, 594–600.
112. Flotte, T. R., Conlon, T. J., Poirier, A., Campbell-Thompson, M., and Byrne, B. J. (2007) Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites, Hum Gene Ther 18, 245–256.
113. Ross, C. J., Twisk, J., Bakker, A. C., Miao, F., Verbart, D., Rip, J., Godbey, T., Dijkhuizen, P., Hermens, W. T., Kastelein, J. J., Kuivenhoven, J. A., Meulenberg, J. M., and Hayden, M. R. (2006) Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation, Hum Gene Ther 17, 487–499.
114. Rivera, V. M., Gao, G. P., Grant, R. L., Schnell, M. A., Zoltick, P. W., Rozamus, L. W., Clackson, T., and Wilson, J. M. (2005) Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer, Blood 105, 1424–1430.
115. Jaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K. M., and Hajjar, R. J. (2009) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial, J Card Fail 15, 171–181.
116. Mendell, J. R., Rodino-Klapac, L. R., Rosales-Quintero, X., Kota, J., Coley, B. D., Galloway, G., Craenen, J. M., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., Campbell, K. J., Bremer, W. G., Viollet, L., Walker, C. M., Sahenk, Z., and Clark, K. R. (2009) Limb- girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann Neurol 66, 290–297.
117. Stroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., High, K. A., Levi, M. M., Hayden, M. R., Kastelein, J. J., and Kuivenhoven, J. A. (2008) Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients, Arterioscler Thromb Vasc Biol 28, 2303–2304.
118. Griffey, M. A., Wozniak, D., Wong, M., Bible, E., Johnson, K., Rothman, S. M., Wentz, A. E., Cooper, J. D., and Sands, M. S. (2006) CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis, Mol Ther 13, 538–547.
119. Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., and Muzyczka, N. (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system, Mol Ther 10, 302–317.
120. Yang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C., Donahue, B. A., Engelhardt, J. F., Kotin, R., and Davidson, B. L. (2002) Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size, J Virol 76, 7651–7660.
121. Glushakova, L. G., Timmers, A. M., Pang, J., Teusner, J. T., and Hauswirth, W. W. (2006) Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors, Invest Ophthalmol Vis Sci 47, 3505–3513.
122. Li, J., Wang, D., Qian, S., Chen, Z., Zhu, T., and Xiao, X. (2003) Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors, Gene Ther 10, 1807–1813.
123. Tuuminen, R., Nykanen, A. I., Krebs, R., Soronen, J., Pajusola, K., Keranen, M. A., Koskinen, P. K., Alitalo, K., and Lemstrom, K. B. (2009) PDGF-A,-C, and-D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts, Arterioscler Thromb Vasc Biol 29, 691–698.
124. Takahashi, H., Kato, K., Miyake, K., Hirai, Y., Yoshino, S., and Shimada, T. (2005) Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice, Clin Exp Rheumatol 23, 455–461.
125. Dai, J., and Rabie, A. B. (2007) Direct AAV-mediated gene delivery to the temporoman-dibular joint, Front Biosci 12, 2212–2220.
126. Wheeler, M. D., Kono, H., Rusyn, I., Arteel, G. E., McCarty, D., Samulski, R. J., and Thurman, R. G. (2000) Chronic ethanol increases adeno-associated viral transgene expression in rat liver via oxidant and NFkappaB-dependent mechanisms, Hepatology 32, 1050–1059.
127. Halbert, C. L., and Miller, A. D. (2004) AAV-mediated gene transfer to mouse lungs, Methods Mol Biol 246, 201–212.
128. Yoshimura, M., Sakamoto, M., Ikemoto, M., Mochizuki, Y., Yuasa, K., Miyagoe-Suzuki, Y., and Takeda, S. (2004) AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype, Mol Ther 10, 821–828.
129. Zaratiegui, M., Castilla-Cortazar, I., Garcia, M., Quiroga, J., Prieto, J., and Novo, F. J. (2002) IGF1 gene transfer into skeletal muscle using recombinant adeno-associated virus in a rat model of liver cirrhosis, J Physiol Biochem 58, 169–176.
130. Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., and Bennett, J. (2001) Gene therapy restores vision in a canine model of childhood blindness, Nat Genet 28, 92–95.
131. Kaplitt, M. G., Xiao, X., Samulski, R. J., Li, J., Ojamaa, K., Klein, I. L., Makimura, H., Kaplitt, M. J., Strumpf, R. K., and Diethrich, E. B. (1996) Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector, Ann Thorac Surg 62, 1669–1676.
132. Ulrich-Vinther, M., Duch, M. R., Soballe, K., O’Keefe, R. J., Schwarz, E. M., and Pedersen, F. S. (2004) In vivo gene delivery to articular chondrocytes mediated by an adeno-associated virus vector, J Orthop Res 22, 726–734.
133. Goodrich, L. R., Choi, V. W., Carbone, B. A., McIlwraith, C. W., and Samulski, R. J. (2009) Ex Vivo Serotype-Specific Transduction of Equine Joint Tissue by Self-Complementary Adeno-Associated Viral Vectors, Hum Gene Ther 20, 1697–1702.
134. Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., Jr., and High, K. A. (2002) Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy, Blood 99, 2670–2676.
135. Rubenstein, R. C., McVeigh, U., Flotte, T. R., Guggino, W. B., and Zeitlin, P. L. (1997) CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector, Gene Ther 4, 384–392.
136. Conrad, C. K., Allen, S. S., Afione, S. A., Reynolds, T. C., Beck, S. E., Fee-Maki, M., Barrazza-Ortiz, X., Adams, R., Askin, F. B., Carter, B. J., Guggino, W. B., and Flotte, T. R. (1996) Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung, Gene Ther 3, 658–668.
137. Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., Tong, G., Potkin, S. G., Fallon, J., Hansen, L., Mufson, E. J., Kordower, J. H., Gall, C., and Conner, J. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease, Nat Med 11, 551–555.
138. Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., Christos, P., Mazumdar, M., Souweidane, M. M., Kaplitt, M. G., and Crystal, R. G. (2008) Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA, Hum Gene Ther 19, 463–474.
139. Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D. J., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G., Sharrar, W., Liouterman, L., Camp, A., Kolodny, E., Samulski, J., and Leone, P. (2002) Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain, Hum Gene Ther 13, 1391–1412.
140. Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., and During, M. J. (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial, Lancet 369, 2097–2105.
141. Wagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A. M., Conrad, C. K., Guggino, W. B., Flotte, T. R., Wine, J. J., Carter, B. J., Reynolds, T. C., Moss, R. B., and Gardner, P. (2002) A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies, Hum Gene Ther 13, 1349–1359.
142. Flotte, T. R., Brantly, M. L., Spencer, L. T., Byrne, B. J., Spencer, C. T., Baker, D. J., and Humphries, M. (2004) Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults, Hum Gene Ther 15, 93–128.
143. Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., Tai, S. J., Herzog, R. W., Arruda, V., Johnson, F., Scallan, C., Skarsgard, E., Flake, A. W., and High, K. A. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector, Nat Genet 24, 257–261.
144. Weber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Cherel, Y., Chenuaud, P., Samulski, J., Moullier, P., and Rolling, F. (2003) Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery, Mol Ther 7, 774–781.
145. Alisky, J. M., Hughes, S. M., Sauter, S. L., Jolly, D., Dubensky, T. W., Jr., Staber, P. D., Chiorini, J. A., and Davidson, B. L. (2000) Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors, Neuroreport 11, 2669–2673.
146. Gorbatyuk, M., Justilien, V., Liu, J., Hauswirth, W. W., and Lewin, A. S. (2007) Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme, Experimental eye research 84, 44–52.
147. Apparailly, F., Khoury, M., Vervoordeldonk, M. J., Adriaansen, J., Gicquel, E., Perez, N., Riviere, C., Louis-Plence, P., Noel, D., Danos, O., Douar, A. M., Tak, P. P., and Jorgensen, C. (2005) Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints, Hum Gene Ther 16, 426–434.
148. Adriaansen, J., Khoury, M., de Cortie, C. J., Fallaux, F. J., Bigey, P., Scherman, D., Gould, D. J., Chernajovsky, Y., Apparailly, F., Jorgensen, C., Vervoordeldonk, M. J., and Tak, P. P. (2007) Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent, Ann Rheum Dis 66, 1143–1150.
149. Kitajima, K., Marchadier, D. H., Burstein, H., and Rader, D. J. (2006) Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1, Atherosclerosis 186, 65–73.
150. De, B., Heguy, A., Leopold, P. L., Wasif, N., Korst, R. J., Hackett, N. R., and Crystal, R. G. (2004) Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin, Mol Ther 10, 1003–1010.
151. Sandalon, Z., Bruckheimer, E. M., Lustig, K. H., Rogers, L. C., Peluso, R. W., and Burstein, H. (2004) Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors, J Virol 78, 12355–12365.
152. Nathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., Mertens, K., and Davidoff, A. M. (2006) Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood 107, 2653–2661.
153. Towne, C., Raoul, C., Schneider, B. L., and Aebischer, P. (2008) Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice, Mol Ther 16, 1018–1025.
154. Sun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., and Koeberl, D. D. (2005) Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter, Mol Ther 11, 889–898.
155. Wang, Z., Allen, J. M., Riddell, S. R., Gregorevic, P., Storb, R., Tapscott, S. J., Chamberlain, J. S., and Kuhr, C. S. (2007) Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy, Hum Gene Ther 18, 18–26.
156. Moscioni, D., Morizono, H., McCarter, R. J., Stern, A., Cabrera-Luque, J., Hoang, A., Sanmiguel, J., Wu, D., Bell, P., Gao, G. P., Raper, S. E., Wilson, J. M., and Batshaw, M. L. (2006) Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors, Mol Ther 14, 25–33.
157. Broekman, M. L., Comer, L. A., Hyman, B. T., and Sena-Esteves, M. (2006) Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain, Neuroscience 138, 501–510.
158. Lawlor, P. A., Bland, R. J., Mouravlev, A., Young, D., and During, M. J. (2009) Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates, Mol Ther 17, 1692–1702.
159. Craig, A. T., Gavrilova, O., Dwyer, N. K., Jou, W., Pack, S., Liu, E., Pechhold, K., Schmidt, M., McAlister, V. J., Chiorini, J. A., Blanchette-Mackie, E. J., Harlan, D. M., and Owens, R. A. (2009) Transduction of rat pancreatic islets with pseudotyped adeno-associated virus vectors, Virol J 6, 61.
160. Nienhuis, A. W. (2007) Discussion of human gene transfer protocol 0707–864: an open-label dose-escalation study of a selfcomple-mentary adeno-associated viral vector (scAAV2/8-LPlhFIXco) for gene therapy of hemophilia B, RAC NIH http://www4.od.nih. gov/oba/rac/meetings/Dec2007/final_RAC_ agenda_dec07.pdf.
161. Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., and Kaspar, B. K. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat Biotechnol 27, 59–65.
162. Xue, Y. Q., Ma, B. F., Zhao, L. R., Tatom, J. B., Li, B., Jiang, L. X., Klein, R. L., and Duan, W. M. (2010) AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson’s disease, Gene Ther 17, 83–94.
163. Bish, L. T., Morine, K., Sleeper, M. M., Sanmiguel, J., Wu, D., Gao, G., Wilson, J. M., and Sweeney, H. L. (2008) Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat, Hum Gene Ther 19, 1359–1368.
164. Limberis, M. P., and Wilson, J. M. (2006) Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered, Proc Natl Acad Sci USA 103, 12993–12998.
165. Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A. M., Fyfe, J., Moullier, P., Colle, M. A., and Barkats, M. (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons, Mol Ther 17, 1187–1196.
166. Klein, R. L., Dayton, R. D., Tatom, J. B., Henderson, K. M., and Henning, P. P. (2008) AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method, Mol Ther 16, 89–96.
167. De, B. P., Heguy, A., Hackett, N. R., Ferris, B., Leopold, P. L., Lee, J., Pierre, L., Gao, G., Wilson, J. M., and Crystal, R. G. (2006) High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses, Mol Ther 13, 67–76.